Chiltern: Asia-Pacific expansion is essential

By Gareth Macdonald

- Last updated on GMT

Related tags Clinical trial Pharmaceutical industry Asia-pacific

Contract research organisation (CRO) Chiltern says new Australia and Singapore offices are a natural progression for its contract research business in the Asia-Pacific region.

Spokeswoman Natalie Chong told Outsourcing-pharma the units “will offer clinical development services; primarily project management and clinical monitoring operations, as well as resourcing solutions services. 

We are also running late Phase trials in the region and expect to add additional services to compliment the mix of trials we run and to address the needs of our strong Asia Pacific client base​.”

Chong explained that customer demand for trials was the key driver for the expansion and predicted that the region has all the ingredients required for continued growth.

In addition to the acceptance of data by regulators and growing acceptance of ICH GCP and regulations facilitation processes, the size of the clinical trial population coupled with the expanding network of investigators in key therapeutic areas of interest to Chiltern makes expansion in this region an essential choice​.”

She went on to say that Chiltern is assessing local acquisition opportunities and plans to set up more offices in Asia-Pacific with the Singapore unit acting as its central clinical trial management hub.

Asia-Pacific’s promise for trials

Chiltern is not the only CRO to recognise growing demand for clinical trials in Asia-Pacific. In the last six months, for example, peers like PRA​, Parexel​ and Covance​ have all expanded their operations in the region.

Asia-Pacific’s attraction as a destination for trials, according to a recent report by Quintiles India CEO Ferzaan Engineer, is better access to patients, lower cost and operational efficiencies.

From a clinical research standpoint, the region remains particularly attractive due to the availability of large pools of potential patients and motivated investigators for clinical trials.

As biopharma companies work to minimize both time- and cost-to-market, Asia, which accounts for more than 60% of the world’s population, continues to offer significant advantages from a logistical, genetic, therapeutic and demographic perspective​.”

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers